Log out Go to App
Go to App

Learning Materials

Features

Discover

Chapter 40: Problem 10

Your brother continues to progress rapidly with no apparent remission even on standard immunotherapy for RR-MS. What therapy is FDA approved for rapidly progressing MS?

Short Answer

Expert verified
Answer: Alemtuzumab is an FDA-approved therapy suitable for rapidly progressing RR-MS when standard immunotherapy does not show significant improvement.

Step by step solution

01

Understanding MS

Multiple Sclerosis (MS) is a disease in which the immune system attacks the protective covering of nerves, causing communication problems between the brain and the rest of the body. There are several types of MS, one of which is Relapsing-Remitting MS (RR-MS). RR-MS is characterized by periods of relapses (new or worsening symptoms) followed by periods of remission (partial or complete recovery from symptoms).
02

FDA-approved Therapies for RR-MS

There are various FDA-approved therapies for RR-MS, which mainly focus on reducing relapse rates and slowing down the progression of the disease. Some of these therapies include interferon-beta, glatiramer acetate, and disease-modifying therapies such as oral medications (e.g., fingolimod, dimethyl fumarate, teriflunomide) and monoclonal antibodies (e.g., natalizumab, ocrelizumab).
03

Identifying Therapy for Rapidly Progressing RR-MS

For cases in which RR-MS is rapidly progressing despite standard immunotherapy, more aggressive forms of treatment may be required. One such therapy that has been FDA-approved is alemtuzumab, a monoclonal antibody that targets a protein called CD52 on the surface of immune cells. By reducing the number of these cells, the immune system's attack on the nerves is lessened, potentially slowing down the progression of the disease.
04

Conclusion

For rapidly progressing RR-MS that does not respond to standard immunotherapy, the FDA-approved therapy to consider is alemtuzumab. It is crucial for the individual to consult their healthcare provider to discuss the suitability of alemtuzumab or other treatment options based on their specific condition and medical history.

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Start your free trial

Over 30 million students worldwide already upgrade their learning with Vaia!

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

The FDA approved therapy for relapsing remitting MS with the smallest \(\%\) reduction in relapses at 12 months by the Johnson Class I data a. Avonex b. Betaseron c. Copaxone d. Rebif

What clinical information, in association with verification of the clinical symptoms of optic neuritis and fatigue would be sufficient to verify that the diagnosis is definitive MS using the revised MacDonald criteria?

This approved therapy for relapsing remitting MS included a warning to monitor depression because of a suicide during the phase III trial. a. Avonex b. Betaseron c. Copaxone d. Rebif

Score for an individual with normal motor function on the Kurtzke Expanded Disability Scoring Scale (EDSS) a. 0 b. 1 c. 5 d. 10

In the Kahn head to head trial which of the following therapies was not evaluated? a. Avonex b. Betaseron c. Copaxone d. Rebif
See all solutions

Recommended explanations on Biology Textbooks

Microbiology

Read Explanation

Control of Gene Expression

Read Explanation

Cells

Read Explanation

Reproduction

Read Explanation

Ecosystems

Read Explanation

Substance Exchange

Read Explanation
View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.

Sign-up for free